IB
MDGL icon

Intrust Bank’s Madrigal Pharmaceuticals MDGL Stock Holding History

Intrust Bank’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$485K Buy
903
+40
+5% +$20.5K 0.04% 276
2026
Q1 		$452K Buy
863
+15
+2% +$7.17K 0.04% 277
2025
Q4 		$494K Buy
848
+174
+26% +$88.9K 0.04% 257
2025
Q3 		$309K Buy
+674
New +$251K 0.03% 332

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Intrust Bank's MDGL Position: Q2 2026 in Review

Intrust Bank increased its Madrigal Pharmaceuticals (MDGL) stake by 4.6% in Q2 2026, buying an estimated $20.5K and bringing the position to 903 shares worth $485K. The position accounts for 0.04% of the portfolio, ranked #276.

Intrust Bank first reported a position in MDGL in Q3 2025 and has held it in 4 quarters since. The position peaked at $494K in Q4 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Intrust Bank held 903 shares of Madrigal Pharmaceuticals worth $485K as of Q2 2026.
  • Intrust Bank bought 40 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $20.5K.
  • Madrigal Pharmaceuticals made up 0.04% of Intrust Bank's portfolio in Q2 2026, its #276 holding.
  • Intrust Bank first reported a position in Madrigal Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Intrust Bank's Madrigal Pharmaceuticals position peaked at $494K in Q4 2025.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Intrust Bank's 13F filing for Q2 2026, filed 5 Aug 2026.